BioCardia Unveils Groundbreaking Results in Phase III CardiAMP Cell Therapy for Heart Failure
BioCardia, Inc., a leader in biotechnological advancements for cardiovascular diseases, recently announced remarkable interim results from its Phase III CardiAMP® Cell Therapy trial for treating advanced chronic heart failure. These findings mark a significant milestone in the pursuit of innovative treatments for heart failure, showcasing the potential of stem cell therapy to revolutionize patient care. […]
BrainStorm Cell Therapeutics Advances ALS Treatment with Phase 3b Trial of NurOwn®
In a significant stride towards combating neurodegenerative diseases, BrainStorm Cell Therapeutics Inc. has announced its submission of a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) for a Phase 3b study of NurOwn®, its pioneering investigational treatment for amyotrophic lateral sclerosis (ALS). This move, following a constructive in-person meeting with […]
Unlocking the Potential of Exosomes in Brain Health: A Leap Forward by Kimera Labs
In the ever-evolving field of regenerative medicine, Mesenchymal Stem Cells (MSCs) and their secreted exosomes represent a frontier of hope for conditions once deemed untreatable. Kimera Labs, a pioneer in MSC exosome research and production, has recently made headlines with its groundbreaking work on brain targeting of exosomes, as highlighted in Nature Scientific Reports. This […]
The Dawn of a New Era in Heart Failure Treatment: BioCardia’s CardiAMP Heart Failure II Phase 3 Pivotal Study
In an exciting development for the field of cardiovascular medicine, BioCardia, Inc., a pioneering biotechnology company, has announced the activation of the CardiAMP Heart Failure II Phase 3 pivotal study. This groundbreaking study, recently greenlit by the FDA, represents a significant leap forward in the treatment of ischemic heart failure through advanced cell therapy techniques. […]
Coeptis Therapeutics Advances with Groundbreaking Stem Cell Therapy in Phase 2 Program
In a significant stride towards revolutionizing the treatment of viral infections, Coeptis Therapeutics, Inc., a name synonymous with innovation in the biopharmaceutical realm, has announced its plans to embark on a Phase 2 program. This program is centered around its proprietary, first-in-class allogeneic NK cell therapy, showcasing a pivotal moment in the pursuit of advanced […]
SmartCella: Pioneering the Future of Cell Therapy Manufacturing
In a significant leap forward for the biotechnology industry, SmartCella, through its business unit ProCella, has recently secured approval from the Swedish Medicinal Product Agency for the manufacturing and quality control testing of sterile biological medicinal products for cell therapy. This landmark achievement underscores SmartCella’s commitment to advancing the field of cell-based therapies and marks […]
Mirus Bio Achieves ISO 13485:2016 Certification: A Milestone in Quality Management
Mirus Bio, a renowned life sciences company, has recently marked a significant milestone by achieving the ISO 13485:2016 certification. This accomplishment underscores the company’s commitment to maintaining the highest quality standards in its operations, particularly in the development of innovative solutions for nucleic acid delivery, which are crucial in cell and gene therapy production, biopharmaceutical […]
Pioneering Neurodegenerative Disease Research with Stem Cell-Derived Brain Organoids in Space
The Groundbreaking Mission: In a significant leap towards understanding neurodegenerative disorders, the International Space Station National Lab is hosting an innovative research project. This project involves stem cell-derived brain organoids being sent to space as part of Axiom Space’s third private astronaut mission. The objective is to improve the modeling of diseases like Parkinson’s disease […]
CRISPR Therapeutics’ FDA Approval for CASGEVY™
CRISPR Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving CASGEVY™ (exagamglogene autotemcel [exa-cel]), a groundbreaking CRISPR/Cas9 gene-edited cell therapy. This approval makes CASGEVY available for the treatment of transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older. Approximately 1,000 patients in the U.S. are now eligible for […]
Innovative Breakthrough: BioRestorative Therapies Secures Key Patent for Obesity Treatment Program
BioRestorative Therapies, Inc., a pioneering clinical-stage company specializing in stem cell-based therapies, has achieved a significant milestone in its quest to combat obesity and metabolic disorders. The United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the company’s ThermoStem® program. This development, announced on December 12, […]